Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Corporate Governance

Overview

Our commitment to scientific excellence, operational efficiency, and customer focus positions us as a preferred partner in the industry. In this section, we highlight how Sai Life Sciences drives growth through strategic investments in infrastructure, technology and talent, all aimed at delivering value to our stakeholders.

Financial Information
Annual Reports
Corporate Governance
Shareholder Service
Disclosures

Corporate Governance

Dr. K. Ranga Raju

Chairman

Krishna Kanumuri

Managing Director and CEO

Siva Chittor

Whole-Time Director & Chief Financial Officer

Ramesh G Iyer

Independent Director

Suchita Sharma

Independent Director

Dr. Dinesh V Patel

Independent Director

Siva Chittor

Whole-Time Director & Chief Financial Officer

Runa Karan

Company Secretary, Compliance Officer & Legal Head

Key items

Download

Committees of the board

Download

Key items

Download

CG Report for Quarter ending 30.09.2025

Download

CG Report for Quarter ending 30.06.2025

Download

CG Report for Quarter ending 31.03.2025

Download

CG Report for Quarter ending 31.12.2024

Download

Key items

Download

Basis of Allotment (BoA) AD

Download

Prospectus

Download

Red Herring Prospectus

Download

Draft Red Herring Prospectus

Download

Frost & Sullivan Industry Report

Download

Corporate Policies/Documents

Key items

Download

Familiarisation Programme for ID-FY26

Download

Management ESOP Scheme 2018

Download

ESOP Scheme 2008

Download

Criteria for Making Payments to Non-Executive Directors

Download

Anti-Sexual Harassment Policy

Download

Archival Policy

Download

Code of Conduct for BoD and SMPs

Download

Code of conduct for NEDs

Download

Corporate Social Responsibility Policy

Download

Determining Material Subsidiaries

Download

Disclosure of Contact details of KMP as per Reg 30(5)

Download

Familiarisation Programme for Id

Download

Nomination and Remuneration Policy

Download

Policy for Evaluation of Performance of BoD

Download

Policy for Familiarisation Programme for ID

Download

Policy for Preservation of Documents

Download

Policy for Determination of Materiality

Download

Policy on Related Party Transactions

Download

Policy to Promote Diversity of Board of Directors

Download

Risk Management Policy

Download

Code of Practices-Fair Disclosure of UPSI

Download

Insider Trading Policy

Download

Succession Policy

Download

Terms and Conditions for appointment of Independent Director

Download

UPSI Leak Inquiry Policy

Download

Whistle Blower Policy

Download

Material Contracts

Key items

Download

Offer Agreement

Download

Amendment to Offer Agreement

Download

Registrar Agreement

Download

Amendment to Registrar Agreement

Download

Monitoring Agency Agreement

Download

Cash Escrow and Sponsor Banks Agreement

Download

Share Escrow Agreement

Download

Syndicate Agreement

Download

Material Documents

Key items

Download

Certificate of Commencement for Business

Download

Annual Reports of the Company for Fiscal year 2022

Download

Annual Reports of the Company for Fiscal year 2023

Download

Annual Reports of the Company for Fiscal year 2024

Download

Agreement dated November 27, 2023 along-with amendment agreement dated July 10, 2024

Download

BR taking on record the approval for OFS by each of selling shareholders

Download

BR Approving RHP

Download

Tripartite agreement between Company, NSDL and Registrar of the Offer

Download

BR Approving the Offer and Related Matters

Download

Tripartite agreement between Company, CDSL and Registrar of the Offer

Download

Certificate of Incorporation

Download

Vishvakarma Consultancy Services Consent Letter

Download

Consent letters and authorisations from selling shareholders

Download

Consents by Directors, Company Secretary, Compliance Officer and Legal Head, legal counsels to the Company, Bankers to the Company, Banker(s) to the Offer, the BRLMs, Syndicate Members, Registrar to the offer to act in respective capacities

Download

Deloitte Consent Letter

Download

Due diligence certificate dated July 24, 2024

Download

BR Approving DRHP

Download

Frost & Sullivan consent

Download

Gift Deed along-with supplementary letter

Download

In-principle listing approvals by NSE and BSE

Download

Frost & Sullivan report

Download

Loan utilization certificate

Download

Certified Copies of MoA and AoA

Download

BR and SR for approval of revised remuneration structure of Chairman and WTD

Download

Certificate by Bashetty & Joshi certifying Basis for Offer price

Download

Certificate by Bashetty & Joshi certifying details of Employee Stock options scheme

Download

Certificate by Bashetty & Joshi certifying details of outstanding borrowings

Download

Certificate by Bashetty & Joshi certifying KPIs

Download

Certificate by Bashetty & Joshi certifying dues owed to material creditors, MSME enterprises and other creditors

Download

Certificate by Bashetty & Joshi certifying weighted average cost of acquisition

Download

Examination Report

Download

Statement of Possible Special Tax Benefits certificate

Download

Scheme of arrangement between Company, Sai Quest Syn and their respective shareholders and creditors along-with Valuation report

Download

SEBI Final observation letter

Download

Shareholders’ agreement dated March 27, 2019 along-with amendment agreement dated July 4, 2024

Download

SR Approving Fresh Issue and Other Related Matters

Download

IPO committee resolution taking on record consent to participate in OFS by each of selling shareholders

Download

Audit committee resolution approving KPIs for disclosure

Download

BR and SR for approval of revised remuneration structure of MD and CEO

Download

Compliance

Key items

Download

EPFO Form 5A

Download

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube